Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking FDA milestones and neuromodulation breakthroughs at NeuroOne Medical Technologies Corp often means digging through hundreds of technical pages. Whether you’re searching for capital-intensive R&D figures or the latest thin-film electrode patent updates, NeuroOne’s disclosures can feel overwhelming.
Stock Titan solves that problem. Our AI reads every new document the instant it hits EDGAR, then delivers clear takeaways you can act on. Need the NeuroOne Medical Technologies quarterly earnings report 10-Q filing? We tag revenue from clinical evaluations and spotlight changes in cash burn. Curious about NeuroOne Medical Technologies insider trading Form 4 transactions? Real-time alerts surface each executive purchase or sale so you can gauge management’s confidence. The platform also breaks down:
- NeuroOne Medical Technologies annual report 10-K simplified – see FDA submission timelines, manufacturing scale-up costs, and segment revenue in minutes.
- NeuroOne Medical Technologies 8-K material events explained – from pivotal trial results to licensing agreements, our summaries flag what moves the stock.
- NeuroOne Medical Technologies proxy statement executive compensation – understand option grants tied to device approvals without wading through tables.
All filings—10-K, 10-Q, 8-K, S-1, plus every NeuroOne Medical Technologies Form 4 insider transactions real-time—are updated automatically. Investors use our AI-powered summaries to compare quarter-over-quarter R&D spend, monitor patent additions, and track NeuroOne Medical Technologies executive stock transactions Form 4 before key announcements. If you’ve ever typed “understanding NeuroOne Medical Technologies SEC documents with AI” or looked for “NeuroOne Medical Technologies earnings report filing analysis,” you’re in the right place. Complex med-tech disclosures made clear—so you can focus on decision-making, not document hunting.
NeuroOne Medical Technologies (NMTC) received a Nasdaq extension to regain compliance with the Nasdaq Capital Market’s Minimum Bid Price Requirement of $1.00 per share. Nasdaq granted a 180-day extension through May 4, 2026.
The extension has no immediate effect on the company’s listing; NMTC’s common stock remains fully listed on the Nasdaq Capital Market. The company previously had until November 3, 2025 to cure the deficiency and has not yet regained compliance.
NeuroOne plans to continue monitoring the closing bid price and to seek compliance within the extension period. If compliance is not regained by the new deadline, Nasdaq may notify the company that its common stock is subject to delisting, and the company would have the right to appeal to a Nasdaq Hearing Panel.
NeuroOne Medical Technologies Corporation reported an annual total product revenue of approximately
NEUROONE MEDICAL TECHNOLOGIES (NMTC) Chief Technology Officer Steve Mertens reported a sale of 906 shares of common stock on 09/30/2025 at a reported price of $0.8886 per share. After the transaction he beneficially owns 161,329 shares, held directly. The Form 4 was signed by an authorized representative on 10/01/2025.
Insider sale reported: Mark Christianson, Business Development Director of NeuroOne Medical Technologies (NMTC), reported a disposition of 253 shares of the company's common stock on 09/30/2025 at a reported price of $0.8886 per share. After the transaction he beneficially owns 230,985 shares in a direct capacity. The Form 4 was signed by Emily Johns by power of attorney on 10/01/2025. The filing indicates the report was made by one reporting person and lists Christianson\'s Eden Prairie, MN address.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) director and CEO David A. Rosa reported a small sale of 2,458 shares of common stock at $0.8886 per share on 09/30/2025, leaving beneficial ownership of 1,156,373 shares. The filing documents a routine insider disposition while the reporting person retains a substantial equity stake, and the transaction was disclosed under Section 16 rules.
NeuroOne Medical Technologies (NMTC) insider sale disclosed on Form 4. The reporting person, Mark Christianson, identified as a director and Business Development Director, sold 30,000 shares of common stock on 09/05/2025 at a weighted average price of $0.7401 per share, with individual sale prices ranging from $0.7400 to $0.7518. After the reported transactions, the filing shows 231,238 shares beneficially owned. The Form 4 was signed by a power of attorney on 09/09/2025. No derivative securities are reported on this form.
NeuroOne Medical Technologies (NMTC) filed a Form 144 disclosing a proposed sale of 30,000 common shares through Edward Jones with an aggregate market value of $24,210. The filing lists 49,817,835 shares outstanding and an approximate sale date of 08/20/2025. The shares were acquired on 07/01/2025 as an award from NeuroOne Medical Technologies; the record shows 622,000 shares were acquired on that date and payment/nature is indicated as awarded. The filer reports no securities sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Neuroone Med Technologies (NMTC)?
What is the market cap of Neuroone Med Technologies (NMTC)?
